Biohaven Ltd — Cash Flow (NYSE:BHVN) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities -297.69 M-331.73 M-582.45 M -649.52 M Cash from investing activities -304.79 M129.83 M-244.97 M 226.62 M Cash from financing activities 767.6 M211.91 M677.77 M 523.17 M Free cash flow -303.76 M-334.77 M-586.5 M -650.27 M

Nouvelles

Piper Sandler réitère sa note sur l’action Biohaven après l’essai sur l’épilepsie

Piper Sandler reiterates Biohaven stock rating on epilepsy trial

Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?

Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect?

Goldman Sachs initiates coverage on Biohaven Pharma stock with Buy rating

Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?

Biohaven stock rating upgraded by RBC Capital on promising CNS data

This Albemarle Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Albemarle (NYSE:ALB), ARM Holdings (NASDAQ:ARM)

Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know - Biohaven (NYSE:BHVN)

Biohaven rapporte des données cliniques préliminaires sur les programmes de néphropathie IgA, de maladie de Basedow, d'épilepsie, d'obésité et d'oncologie; démontre une dégradation rapide des protéines, des réponses cliniques robustes et des profils de...

Biohaven Ltd. (BHVN) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NYSE:BHVN) 2026-01-12

L’action Biohaven maintient sa note Surperformance chez Baird grâce à des données prometteuses sur l’IgAN